JCO Global Oncology (Sep 2023)

Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting

  • Brooke E. Wilson,
  • Richard Sullivan,
  • Richard Peto,
  • Bello Abubakar,
  • Christopher Booth,
  • Gustavo Werutsky,
  • Cary Adams,
  • Agnes Saint-Raymond,
  • Thomas R. Fleming,
  • Kim Lyerly,
  • Julie R. Gralow

DOI
https://doi.org/10.1200/GO.23.00294
Journal volume & issue
no. 9

Abstract

Read online

Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countries, whereas patients in low- and middle-income countries (LMICs) continue to experience challenges in accessing timely and guideline concordant care. In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development. Panelists discussed key barriers such as the lack of diagnostic services and human resources, drug accessibility and affordability, lack of research infrastructure, and regulatory and authorization challenges, with a particular focus on Africa and Latin America. Potential opportunities to improve access and affordability were reviewed, such as the importance of prioritizing investments in diagnostics, investing health infrastructure and work force planning, coordinated drug procurement efforts and streamlined regulatory processing, incentivized pricing through regulatory change, and the importance of developing and promoting clinical trials that can answer relevant clinical questions for patients in LMICs. As a cancer community, we must continue to advocate for and work toward equitable access to high-quality interventions for patients, regardless of their geographical location.